AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comSEP 12 min read$ASND

Wall Street Analysts Are Bullish on Top Healthcare Picks

Analysts at Jefferies, Evercore ISI, and BMO Capital maintained Buy ratings on Ascendis Pharma (ASND), Alnylam Pharma (ALNY), and Crispr Therapeutics (CRSP), with price targets of $330, $325.20, and $76 respectively. The consensus ratings are Strong Buy for ASND and ALNY, and Moderate Buy for CRSP, with average price targets indicating potential upside.

Original reporting
theglobeandmail.com
Published Sep 1, 2026, 1:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 1:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Wall Street Analysts Are Bullish on Top Healthcare Picks — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$ASNDBullishMed
01

Why it matters

The upgrades may trigger short‑term buying pressure in each stock.

02

Market read

Analyst upgrades provide new actionable insight for three biotech stocks.

03

What to watch

No new clinical data; upgrades rely on expectations.

Relevance 5/10Novelty 5/10Timing: today

Background

Three analysts issued fresh Buy ratings and higher price targets for Ascendis Pharma, Alnylam Pharma, and Crispr Therapeutics.

Company-level read

Ticker impact

$ASNDBullishMedium confidence
Context

Jefferies maintained a Buy rating on Ascendis Pharma and set a new price target of $330.

Expected impact

Potential upside of ~30% from current levels.

Evidence & confidence

Buy rating and higher target suggest near‑term buying interest.

$ALNYBullishMedium confidence
Context

Evercore ISI maintained a Buy rating on Alnylam Pharma and raised the price target to $325.20.

Expected impact

Potential upside of ~35% from current levels.

Evidence & confidence

Buy rating and higher target indicate renewed confidence.

$CRSPBullishMedium confidence
Context

Evercore ISI maintained a Buy rating on Crispr Therapeutics and set a price target of $76.

Expected impact

Potential upside of ~25% from current levels.

Evidence & confidence

Buy rating and target suggest positive sentiment.

Market effects

Sector

Analyst bullishness may lift broader healthcare biotech sentiment.

Regional

US biotech sector may see modest inflows.

Global

Limited to investors tracking biotech equities.

Counterpoint

What could challenge this read

Ratings could be premature if upcoming trial data disappoints.

Key entities

  • Analyst
    Jefferies

    Issued Buy rating for Ascendis Pharma.

  • Analyst
    Evercore ISI

    Issued Buy ratings for Alnylam Pharma and Crispr Therapeutics.

Read at source← All news

Related articles

OCT 12
$ALNYMed

SMC accepts vutrisiran for eligible patients in Scotland

The Scottish Medicines Consortium approved vutrisiran for adults with ATTR-CM, enabling access via NHS Scotland. Developed by Alnylam, vutrisiran is a long-acting treatment targeting the underlying biology of the condition. Around 1,800 people in Scotland may be affected. The therapy is also indicated for hereditary ATTR amyloidosis. The decision follows a similar recommendation by NICE in England and Wales.

pharmatimes.com3 min
OCT 9
$CRSPMedAI 8/10

H.C. Wainwright reiterates Buy on CRISPR stock, $80 target

H.C. Wainwright reiterated a Buy rating and $80 price target for CRISPR Therapeutics (CRSP), citing potential upside from its current $50.44 share price. The stock has declined 9% over the past week. CRISPR will present Phase 1b data for CTX310 at the AHA conference, with analysts noting significant triglyceride reductions. The company's Fair Value is currently above its trading price, according to InvestingPro.

investing.com1 min
OCT 2
$CRSPMedAI 8/10

CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026

CRISPR Therapeutics (CRSP) will present Phase 1 clinical data on its gene-edited CAR T cell therapy, zugocabtagene geleucel (zugo-cel), for autoimmune diseases at the ACR Convergence 2026. The presentation focuses on the therapy's safety and efficacy in treating refractory systemic sclerosis. CRISPR Therapeutics is a biopharmaceutical company developing gene-based medicines, with a pipeline spanning various diseases.

globenewswire.com1 min
SEP 26
$SNOWMed

Snowflake, Palo Alto, Dell, GameStop, Crispr Insider Shock

Insiders at Snowflake (SNOW), Palo Alto (PANW), Dell (DELL), GameStop (GME), and Crispr (CRSP) made notable trades. SNOW's CRO sold $253,951 in shares, PANW's director sold $7.5M, DELL saw multiple sales totaling $22.9M, GME's CEO bought $26.4M in shares, and CRSP's shareholder sold $780,934. These transactions may signal insider expectations.

tipranks.com2 min